Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (261-270 of 499) with videos related to

Pageof 50
Sort By:
Nature Medicine|January 25, 2025
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trialScott Kopetz, Takayuki Yoshino, Eric Van Cutsem, et al.
Advances in Therapy|March 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306Jianming Xu, Ken Kato, Richard Hubner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 StudyJames C Yao, Marianne Pavel, Catherine Lombard-Bohas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische OnkologieManfred P Lutz, Hansjochen Wilke, D J Theo Wagener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.
The Oncologist|June 22, 2014
Quality of life in the trastuzumab for gastric cancer trialTaroh Satoh, Yung-Jue Bang, Evgeny A Gotovkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II studyJean-Luc Van Laethem, Pascal Hammel, Françoise Mornex, et al.
Endocrine-Related Cancer|January 23, 2019
Genomic profiling of NETs: a comprehensive analysis of the RADIANT trialsJames Yao, Abhishek Garg, David Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidinesHeinz-Josef Lenz, Eric Van Cutsem, Shirin Khambata-Ford, et al.
Cancer Treatment Reviews|September 30, 2015
Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensusRené Adam, Aimery de Gramont, Joan Figueras, et al.
Pageof 50

Showing results (261-270 of 499) with videos related to

Sort By:
Pageof 50
Nature Medicine|January 25, 2025
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trialScott Kopetz, Takayuki Yoshino, Eric Van Cutsem, et al.
Advances in Therapy|March 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306Jianming Xu, Ken Kato, Richard Hubner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 StudyJames C Yao, Marianne Pavel, Catherine Lombard-Bohas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische OnkologieManfred P Lutz, Hansjochen Wilke, D J Theo Wagener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.
The Oncologist|June 22, 2014
Quality of life in the trastuzumab for gastric cancer trialTaroh Satoh, Yung-Jue Bang, Evgeny A Gotovkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II studyJean-Luc Van Laethem, Pascal Hammel, Françoise Mornex, et al.
Endocrine-Related Cancer|January 23, 2019
Genomic profiling of NETs: a comprehensive analysis of the RADIANT trialsJames Yao, Abhishek Garg, David Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidinesHeinz-Josef Lenz, Eric Van Cutsem, Shirin Khambata-Ford, et al.
Cancer Treatment Reviews|September 30, 2015
Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensusRené Adam, Aimery de Gramont, Joan Figueras, et al.
Pageof 50